Navigation Links
Verenium Announces $22.5 Million, Five-Year Secured Financing
Date:12/10/2012

ment team," said Richard Pines, a Partner of Athyrium. "We believe this transaction enables Verenium to continue to deploy its proven technology by creating highly differentiated enzyme products across a wide range of sectors and industrial applications."

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

About Athyrium Opportunities Fund

Athyrium Opportunities Fund is a New York-based fund focusing on investment opportunities in the global healthcare sector. The Athyrium investment team has substantial healthcare investment experience across a wide range of asset classes, including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across healthcare verticals, including biopharma, medical devices and products, and healthcare services. The team partners with management teams to implement creative financing solutions to companies' capital needs.

Forward Looking Statements For Verenium

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to commercialize its products, enhance its manufacturing capabilities, capture near-term and longer-term growth and prospects, and reach profitability.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic fo
'/>"/>

SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... KENILWORTH, N.J., Dec. 10 The Board of Directors of Schering-Plough ... of 6.5 cents per common share. Payment will be made ... of business on Feb. 6, 2009. As of Sept. 30, ... , The Board of Directors today also declared ...
... Published in the Journal Blood for the American Society of ... SOMERSET, N.J., Dec. 10 Alfacell Corporation (Nasdaq: ... annual meeting abstracts in Blood (2008 112: Abstract ... and R-Amphinase (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia ...
... December 10 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SIX ... medical research project findings will be presented ... Care) Congress in,Anaheim, California. These studies confirm ... using Oridion Microstream(R) capnography technology,and clearly show ...
Cached Biology Technology:Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... The Quaking gene, first described as a mutation in ... tumor formation and protect humans from cancer. , ... the University of Wisconsin has shown that the Quaking ... a protein associated with GLI1, a cancer-causing oncogene highly ...
... Research Center at Oregon Health & Science University (OHSU) ... how stem cells become various kinds of brain cells. ... Parkinson's disease, brain and spinal cord injury, and other ... lost or damaged brain cells. The research is published ...
... olive oil, which have antioxidant, anti-inflammatory and anti-clotting ... the so-called Mediterranean Diet, according to a new ... the Journal of the American College of Cardiology. ... of the Mediterranean diet on cardiovascular disease and ...
Cached Biology News:Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3OHSU discovery sheds light into how stem cells become brain cells 2Phenolic compounds may explain Mediterranean diet benefits 2Phenolic compounds may explain Mediterranean diet benefits 3
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known maize microRNAs ...
...
Biology Products: